Breaking News Instant updates and real-time market news.

SNBR

Sleep Number

$46.69

0.48 (1.04%)

, UAL

United Airlines

$87.90

0.9 (1.03%)

18:58
10/15/19
10/15
18:58
10/15/19
18:58

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Sleep Number (SNBR) up 6.6%... United Airlines (UAL) up 1.5%. ALSO HIGHER: McKesson (MCK) up 7.8%, AmerisourceBergen (ABC) up 7.5%, Cardinal Health (CAH) up 4.9% after WSJ speculation of potential $18B opioid litigation settlement... Fulton Financial (FULT) up 1.5% after announcing $100M buyback... Eaton (ETN) up 1.1% after selling its Lighting business for $1.4B... Stitch Fix (SFIX) up 1.1% after $3.1M insider buy... MGM Resorts (MGM) up 1.0% after selling Bellagio to Blackstone for $4.25B. DOWN AFTER EARNINGS: JB Hunt (JBHT) down 1.9%... Interactive Brokers (IBKR) down 1.4%. ALSO LOWER: Rhythm Pharmaceuticals (RYTM) down 11.4% after equity offering... ProQR Therapeutics (PRQR) down 10.0% after sepofarsen RPD designation from FDA... Natera (NTRA) down 5.9% after equity offering... Principia Biopharma (PRNB) down 3.0% after equity offering... U.S. Steel (X) down 1.9% after convertible note offering... Arco Platform (ARCE) down 1.3% after filing $1.B mixed shelf... Tradeweb Markets (TW) down 1.0% after Q3 guidance, equity offering. Movers as of 18:30ET.

SNBR

Sleep Number

$46.69

0.48 (1.04%)

UAL

United Airlines

$87.90

0.9 (1.03%)

MCK

McKesson

$138.17

4.01 (2.99%)

ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

CAH

Cardinal Health

$47.93

1.16 (2.48%)

FULT

Fulton Financial

$15.90

0.19 (1.21%)

ETN

Eaton

$82.16

1.29 (1.60%)

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

MGM

MGM Resorts

$27.87

-0.1 (-0.36%)

JBHT

J.B. Hunt

$111.65

1.985 (1.81%)

IBKR

Interactive Brokers

$47.43

0.26 (0.55%)

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

PRQR

ProQR Therapeutics

$6.21

-0.09 (-1.43%)

NTRA

Natera

$39.21

1.01 (2.64%)

PRNB

Principia Biopharma

$29.88

0.7 (2.40%)

X

U.S. Steel

$11.43

0.27 (2.42%)

ARCE

Arco Platform

$48.15

0.75 (1.58%)

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 18

    Oct

SNBR Sleep Number
$46.69

0.48 (1.04%)

07/30/19
KEYB
07/30/19
NO CHANGE
KEYB
Industry data show Tempur Sealy, Sleep Number both took Q2 share, says KeyBanc
KeyBanc analyst Bradley Thomas noted that mattress industry association ISPA released data last night for Q2, noting that the data are based on a sample of manufacturers, are not entirely comparable with GAAP accounting, and are "best used for directional and trend analysis, rather than precise measurements of market share." With that said, he noted that ISPA data suggest that mattress dollar sales decreased 5.0% y/y and that unit shipments decreased 10.5% in Q2. ISPA data also indicate that both Tempur Sealy (TPX) and Sleep Number (SNBR) took share in Q2, Thomas said.
10/09/19
10/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Roku (ROKU) upgraded to Outperform from Neutral at Macquarie with analyst Tim Nollen saying the shift to connected television viewing that has been underway in the U.S. for the past few years will follow internationally in the coming years. 2. Chipotle (CMG) upgraded to Hold from Underperform at Gordon Haskett with analyst Jeff Farmer saying the company's sales momentum makes the bear thesis on shares "increasingly untenable." 3. Sleep Number (SNBR) upgraded to Outperform from Market Perform at Raymond James with analyst Bobby Griffin saying Sleep Number's pullback over the last few months creates a more favorable risk/reward setup heading into Q3 earnings and adds that he continues to have a favorable view of the company's business model and product offering, particularly as consumers focus on health and wellness. 4. American Outdoor Brands (AOBC) upgraded to Buy from Hold at Craig-Hallum with analyst Steven Dyer saying he believes valuation is "extremely attractive" and thinks there is a compelling near-term opportunity with potential catalysts upcoming even though he continues to have concerns about a potential longer-term secular decline in firearms. 5. Fannie Mae (FNMA) and Freddie Mac (FMCC) upgraded to Market Perform from Underperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/19
RAJA
10/09/19
UPGRADE
Target $48
RAJA
Outperform
Sleep Number pullback creates favorable risk/reward setup, says Raymond James
Raymond James analyst Bobby Griffin upgraded Sleep Number to Outperform from Market Perform with a $48 price target. In a research note to investors, Griffin says Sleep Number's pullback over the last few months creates a more favorable risk/reward setup heading into third quarter earnings and adds that he continues to have a favorable view of the company's business model and product offering, particularly as consumers focus on health and wellness.
10/09/19
RAJA
10/09/19
UPGRADE
Target $48
RAJA
Outperform
Sleep Number upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Bobby Griffin upgraded Sleep Number to Outperform from Market Perform with a $48 price target.
UAL United Airlines
$87.90

0.9 (1.03%)

09/06/19
BREN
09/06/19
INITIATION
Target $95
BREN
Hold
United Continental initiated with a Hold at Berenberg
Berenberg started United Continental with a Hold rating and $95 price target.
09/06/19
BREN
09/06/19
INITIATION
BREN
Berenberg says big 4 airlines can generate cash, prefers American and Delta
As previously reported, Berenberg analyst Adrian Yanoshik initiated coverage of the four largest U.S. airlines, starting American Airlines (AAL) with a Buy rating and $35 price target, Delta Air Lines (DAL) with a Buy rating and $72 price target, United Continental (UAL) with a Hold rating and $95 price target and Southwest Airlines (LUV) with a Hold rating and $57 price target. Amid market worries over both capacity growth and demand weakness, his work suggests that U.S. airlines can generate free cash flow in "all scenarios but a 9/11-scale shock," Yanoshik tells investors. He thinks airline sector valuations reflect fears, but overlook broadly stable, albeit two-tiered, returns. He would buy American with valuation at multi-year lows as he estimates that American will narrow its margin gap to peers and thinks it debt burden is misunderstood. He would also buy Delta, which Yanoshik calls "arguably the highest-quality airline."
10/11/19
ARGS
10/11/19
DOWNGRADE
ARGS
Hold
Delta Air Lines downgraded on higher costs, slower growth at Argus
Argus analyst John Staszark downgraded Delta Air Lines (DAL) to Hold from Buy following the company's Q3 results, saying that while Delta is among the best managed airlines, he thinks better returns are available elsewhere, as Delta is facing prospects for rising costs and slowing revenue growth. He recommends shares of United Continental (UAL) over Delta. Longer term, he expects Delta to benefit from solid industry fundamentals, including moderate capacity growth, growing ancillary revenue, and rising demand for air travel.
07/29/19
MACQ
07/29/19
DOWNGRADE
MACQ
Neutral
Macquarie warns about pricing pressure among airlines from Southwest competition
Macquarie analyst Susan Donofrio downgraded American Airlines (AAL), Spirit Airlines (SAVE), Hawaiian Holdings (HA), and Alaska Air (ALK) to Neutral from Outperform as part of a broader industry note, saying the competitive environment for these airlines should become "choppy" in the fall of 2019 and in 2020 as Southwest (LUV) attempts to win back market share. The analyst believes that the latter's sizable domestic scope should lead to "unit revenue softness" within the overall pricing structure, through she maintains an Outperform rating on United Airlines (UAL), Delta (DAL) and Allegiant (ALGT) given their ongoing revenue initiatives and minimal overlap with Southwest.
MCK McKesson
$138.17

4.01 (2.99%)

08/06/19
CLVD
08/06/19
NO CHANGE
CLVD
Neutral
Cardinal Health recently lost 2 major accounts, says Cleveland Research
Cleveland Research analyst Rob Eich reports that his contacts indicate that Cardinal Health (CAH)recently lost two large specialty pharmacy contracts, including one to AmerisourceBergen (ABC) and one to McKesson (MCK). He estimates these contracts, which both should transition in about the first 6 months of FY20, represent $2B-$3B in annualized sales and are likely to be a drag on revenue growth of about 125-175 basis points, Eich told investors in a pre-open research note. He keeps a Neutral rating on Cardinal Health shares.
08/05/19
WOLF
08/05/19
DOWNGRADE
WOLF
Peer Perform
McKesson downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded McKesson to Peer Perform from Outperform citing share outperformance.
09/11/19
DBAB
09/11/19
INITIATION
Target $155
DBAB
Hold
McKesson initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated McKesson with a Hold rating and a price target of $155 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, its European business and domestic opioid litigation.
07/22/19
FBCO
07/22/19
INITIATION
Target $143
FBCO
Neutral
McKesson reinstated with a Neutral at Credit Suisse
Credit Suisse analyst Erin Wilson Wright reinstated coverage of McKesson with a Neutral rating and $143 price target. The analyst says her incrementally positive bias stems from evidence of stabilizing trends across the U.S. pharmaceutical supply chain, where she sees relief from easing generic deflation as well as enhanced visibility across branded price inflation and rebate paradigms. That said, with its shares up 26% from a low in March, Wright sees limited room for upside, acknowledging drug pricing scrutiny remains an overhang into an election cycle, along with other potential headwinds such as opioid litigation.
ABC AmerisourceBergen
$83.18

1.6 (1.96%)

05/14/19
RAJA
05/14/19
NO CHANGE
RAJA
Walgreens could target Amerisource, LabCorp if it seeks M&A, says Raymond James
Raymond James analyst John Ransom said he thinks that "the temptation" for Walgreens (WBA) to do "something" in terms of M&A will grow over time and the "something" it may consider could include either acquiring AmerisourceBergen (ABC) or LabCorp (LH). His analysis points to LabCorp being a less complicated, "but much less accretive," deal, said Ransom. Given Walgreens' existing ownership of about a 26% stake in AmerisourceBergen, he estimates 16% accretion from buying the company for $95 per share in cash if he assumes $500M of synergies and $2B of opioid fines financed with debt, the analyst tells investors. Though such a deal would make financial sense, he does not think investors would "be overly excited about the strategic upside," Ransom tells investors. While he argues that LabCorp "offers more strategic upside," such a hypothetical deal also has less financial benefit, according to Ransom.
09/11/19
DBAB
09/11/19
INITIATION
Target $91
DBAB
Hold
AmerisourceBergen initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated AmerisourceBergen with a Hold rating and a price target of $91 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, volumes shifting towards lower-margin customers and opioid litigation.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
CAH Cardinal Health
$47.93

1.16 (2.48%)

08/27/19
ARGS
08/27/19
DOWNGRADE
ARGS
Hold
Cardinal Health downgraded to Hold from Buy at Argus
09/11/19
DBAB
09/11/19
INITIATION
Target $50
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated Cardinal Health with a Hold rating and a price target of $50 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, recent large customer repricings, and opioid litigation.
08/27/19
08/27/19
DOWNGRADE

Fly Intel: Top analyst downgrades
Catch up on today's top analyst downgrades with this list compiled by The Fly: 1. Cardinal Health (CAH) downgraded to Hold from Buy at Argus with analyst David Toung saying the margins of its Pharmaceutical Distribution segment remain under pressure entering FY20 after a 23bps contraction in FY19. 2. Red Robin (RRGB) downgraded to Underperform from Neutral at BofA/Merrill with analyst Gregory Francfort saying he believes the company's earnings growth will "materially miss" consensus expectations in 2020. 3. T-Mobile (TMUS) downgraded to Perform from Outperform at Oppenheimer. 4. Ultrapar (UGP) downgraded to Hold from Buy at Santander. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/27/19
08/27/19
DOWNGRADE

Hold
Cardinal Health downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded Cardinal Health to Hold, saying the margins of its Pharmaceutical Distribution segment remain under pressure entering FY20 after a 23bps contraction in FY19. The analyst cites the management's expectations of margins in this segment declining by high single to low double digits this year because of the pricing of renewal contracts and higher legal expenses related to opioid litigation. Toung adds that he is also concerned with Cardinal Health's sluggish growth in the Medical segment because of the higher operating expenses coming from the integration of Cordis acquisition.
FULT Fulton Financial
$15.90

0.19 (1.21%)

01/17/19
PIPR
01/17/19
DOWNGRADE
Target $17.5
PIPR
Neutral
Fulton Financial downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Matthew Breese downgraded Fulton Financial to Neutral and lowered his price target for the shares to $17.50 from $19. Following the company's Q4 earnings miss, "driven largely by a sizable increase in the provision," the analyst reduced 2019 and 2020 estimates for Fulton by 4%-5%. Further, beyond credit and lower estimates, Breese thinks the Federal Reserve's change in stance towards interest rate hikes will also impact the performance of asset sensitive banks in 2019, including Fulton Financial. The analyst no longer has conviction that Fulton will outperform over the next twelve months.
ETN Eaton
$82.16

1.29 (1.60%)

10/09/19
VERT
10/09/19
DOWNGRADE
Target $85
VERT
Hold
Eaton downgraded to Hold from Buy at Vertical Research
Vertical Research analyst Jeffrey Sprague downgraded Eaton to Hold from Buy with a price target of $85, down from $90.
09/03/19
BARD
09/03/19
DOWNGRADE
Target $82
BARD
Neutral
Eaton downgraded to Neutral at Baird
As reported previously, Baird analyst Mig Dobre downgraded Eaton to Neutral from Outperform. The analyst noted the Electrical business has performed well but he sees a slowdown with orders and backlog already showing signs of deceleration. He also said the Hydraulics and Vehicles businesses will remain pressured. Dobre lowered his price target to $82 from $89 on Eaton shares.
09/11/19
JPMS
09/11/19
NO CHANGE
JPMS
In Machinery shift, JPMorgan upgrades Agco and Oshkosh, cuts Actuant
With her U.S. Machinery coverage universe underperforming the broader market year-to-date, but outperforming since Labor Day amid a rotation into cyclicals, JPMorgan analyst Ann Duignan established December 2020 price targets based on where she believes we are in the cycle for end market demand. The analyst sees North America and Europe truck demand at or beyond peak, North America construction equipment "perhaps rolling over" in 2020, North America agriculture equipment demand "likely stagnating" near mid-cycle, and mining equipment "slowly approaching" mid-cycle. Within this framework, Duignan this morning upgraded both Agco (AGCO) and Oshkosh (OSK) to Overweight from Neutral, saying both stocks look undervalued with relatively limited downside risk to earnings estimates. Additionally, the analyst downgraded Actuant (ATU) to Underweight from Neutral, saying the risks appear weighted to the downside at current valuation levels. She sees elevated risk of management overpaying for acquisitions should it pursue the pipeline of potential targets. Duignan also maintained Overweight ratings on Eaton (ETN), Caterpillar (CAT) and Terex (TEX), and Underweight ratings on Deere (DE) and Allison Transmission (ALSN).
09/19/19
ROTH
09/19/19
NO CHANGE
Target $95
ROTH
Sell
Acuity competition to intensify on Eaton Cooper Lighting sale, says Roth Capital
Roth Capital analyst Craig Irwin notes that sources say Eaton (ETN) should announce the disposal of Cooper Lighting in the next few days, which would mark a major competitive shift in the U.S. lighting market. There are only a few logical buyers, but the identity and price are still uncertain, he adds, arguing that what is nearly certain is a new owner is likely to remove Eaton's corporate-mandated headwinds on the business including a backwards travel policy, and anti-competitive project variance process. Irwin expects Acuity Brands (AYI) to see incremental competitive pressure. He has a Sell rating and $95 price target on Acuity's shares.
SFIX Stitch Fix
$20.83

-0.38 (-1.79%)

10/08/19
STFL
10/08/19
NO CHANGE
Target $28
STFL
Buy
Stifel maintains favorable view of Stitch Fix after 'better than feared' Q4
Stifel analyst Scott Devitt said that despite the fact that some investors have expressed concerns over Stitch Fix's Q1 and FY20 profitability guidance, he thinks the company's Q4 results were "better than feared," he believes the company is right to invest to expand the platform and enhance the user experience and he sees a number of tailwinds for its longer-term growth. Devitt reiterated his Buy rating and $28 price target on Stitch Fix shares.
10/15/19
BARD
10/15/19
INITIATION
Target $28
BARD
Outperform
Stitch Fix started with Outperform, risk/reward attractive says Baird
Baird analyst Mark Altschwagger initiated coverage of Stitch Fix with an Outperform rating and $28 price target. Altschwager said the company offers a highly differentiated shopping experience, capable of capturing increased share of a highly fragmented apparel & accessories market. He said the future looks bright and the risk/reward is attractive.
10/15/19
10/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. iHeartMedia (IHRT) initiated with a Neutral at Goldman Sachs. 2. Stitch Fix (SFIX) initiated with an Outperform at Baird. 3. eHealth (EHTH) initiated with an Outperform at Raymond James. 4. Drive Shack (DS) initiated with an Outperform at JMP Securities. 5. Amarin (AMRN) initiated with a Neutral at Goldman amid 'bullish' consensus expectations. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/14/19
BARD
10/14/19
INITIATION
Target $28
BARD
Outperform
Stitch Fix initiated with an Outperform at Baird
Baird analyst Mark Altschwagger initiated coverage of Stitch Fix with an Outperform rating and $28 price target.
MGM MGM Resorts
$27.87

-0.1 (-0.36%)

08/02/19
BOFA
08/02/19
DOWNGRADE
Target $31
BOFA
Neutral
BofA/Merrill downgrades MGM to Neutral on balanced risk/reward
BofA/Merrill analyst Shaun Kelley downgraded MGM Resorts to Neutral from Buy with an unchanged price target of $31. The analyst views the risk/reward as more balanced at current share levels. Potential catalysts from the ramp of MGM Cotai in Macau, real estate optionality and the MGM 2020 Plan are balanced by rising cyclical risks, convention competition, and the company's high operating leverage, Kelley tells investors in a research note.
09/17/19
MSCO
09/17/19
NO CHANGE
MSCO
Las Vegas Sands, MGM, Wynn targets cut at Morgan Stanley on Macau estimate cuts
Morgan Stanley analysts Thomas Allen and Praveen Choudhary lowered their expectations for Macau, stating they now expects gross gaming revenue to decline 3% in 2019 and grow 3% in 2020. The analysts previously forecast a 1% decline in GGR for 2019 and an 8% increase in 2020. Allen lowered his price target on Las Vegas Sands (LVS) to $66 from $68, cut his target on MGM Resorts (MGM) to $31 from $32 and reduced his Wynn Resorts (WYNN) target to $115 from $129, explaining that the Wynn cut is most pronounced since it is most exposed to Macau and to the weak high-end there. He maintains an Overweight rating on Las Vegas Sands, which he views as the most defensive and with potential Japan upside. Allen has Equal Weight ratings on MGM and Wynn shares.
08/22/19
MSCO
08/22/19
NO CHANGE
MSCO
Las Vegas Sands' Osaka decision good for it and MGM, says Morgan Stanley
After Las Vegas Sands (LVS) announced that it is not pursuing a license in Osaka, choosing to focus on Tokyo and Yokohama, Morgan Stanley analyst Thomas Allen said he believes the company may be making the right long-term decision. He also views the news as a potential positive for MGM Resorts (MGM), which he thinks is now "in pole position" to win the Osaka license. Both MGM and Las Vegas Sands will face intense competition from other global gaming companies for licenses in Japan, added Allen.
09/06/19
JPMS
09/06/19
NO CHANGE
JPMS
JPMorgan sees number of events hurting Macau gross gaming revenue
A number of events are negatively impacting Macau gross gaming revenue performance, including increasing China-U.S. trade tensions, Hong Kong protests, slowing economic growth in Mainland China, and potential issues related to the city's largest junket, JPMorgan analyst Joseph Greff tells investors in a research note. As a result, the analyst lowered his Macau property level estimates for the four U.S. listed Macau operators, Las Vegas Sands (LVS), MGM Resorts (MGM), Melco Resorts & Entertainment (MLCO) and Wynn Resorts (WYNN). Greff, however, continues to see value in the Macau operators. He keeps a Neutral rating on Las Vegas Sands and dropped his price target to $60 from $68, an Overweight rating on MGM and lowered his price target to $36 from $37, an Overweight rating on Melco and lowered his price target to $25 from $29, and an Overweight rating on Wynn Resorts with a slightly reduced price target of $136.
JBHT J.B. Hunt
$111.65

1.985 (1.81%)

09/11/19
LOOP
09/11/19
DOWNGRADE
Target $121
LOOP
Hold
J.B. Hunt downgraded to Hold from Buy at Loop Capital
Loop Capital analyst Rick Paterson downgraded J.B. Hunt Transport Services to Hold from Buy with a $121 price target.
09/11/19
09/11/19
DOWNGRADE
Target $121

Hold
J.B. Hunt downgraded to Hold at Loop Capital on valuation
As previously reported, J.B. Hunt analyst Rick Paterson downgraded J.B. Hunt to Hold from Buy while keeping his price target at $121, saying the rebound in the stock has taken it to within 4% of that level and no longer warrants a bullish stance. The analyst also attributes the rating change to his caution regarding the downdraft in pricing "across the transportation complex", to which J.B. Hunt is not immune. Paterson adds that the macro negatives for the stock include the likelihood of a mild recession in the U.S. and the China trade war, which is likely to get worse before it gets better.
10/08/19
SUSQ
10/08/19
DOWNGRADE
SUSQ
Neutral
J.B. Hunt downgraded to Neutral from Positive at Susquehanna
10/08/19
SUSQ
10/08/19
DOWNGRADE
Target $119
SUSQ
Neutral
J.B. Hunt downgraded to Neutral at Susquehanna
As reported previously, Susquehanna analyst Bascome Majors downgraded J.B. Hunt (JBHT) to Neutral from Positive. He now has a more conservative view on its earnings outlook and is more cautious on the intermodal space and the stock's valuation. Majors also noted that his top pick in the space remains Knight-Swift (KNX). Majors lowered his price target to $119 from $124 on J.B.Hunt shares.
IBKR Interactive Brokers
$47.43

0.26 (0.55%)

10/02/19
10/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Spotify (SPOT) upgraded to Neutral from Underperform at Credit Suisse with analyst Brian Russo saying with a "negative narrative" gaining momentum since the summer, expectations for a Q3 subscriber miss are now priced into the stock. 2. Carter's (CRI) upgraded to Buy from Neutral at DA Davidson with analyst John Morris saying he believes that the company is better positioned to beat on earnings expectations heading into the Fall and Holiday seasons with diminished cost and investment pressures as well as subsiding "sector-wide consolidation turbulence." 3. Kratos Defense (KTOS) upgraded to Outperform from Market Perform at Noble Capital with analyst Joe Gomes saying the company is continuing to win awards. 4. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Charles Cerankosky saying his survey pointed to strong customer demand. 5. Interactive Brokers (IBKR) upgraded to Buy from Neutral at Compass Point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/19
COMP
10/02/19
UPGRADE
Target $56
COMP
Buy
Interactive Brokers upgraded to Buy from Neutral at Compass Point
Compass Point analyst Christopher Allen upgraded Interactive Brokers Group to Buy from Neutral with a price target of $56.
10/01/19
GSCO
10/01/19
NO CHANGE
GSCO
Goldman says matching Schwab cut could hit E-Trade, TD Ameritrade EPS by 15%-20%
After Charles Schwab (SCHW) announced it would cut commissions on equities, ETFs and options trades on U.S. and Canadian exchanges from $4.95 per trade to zero, Goldman Sachs analyst Will Nance estimated this move will lower the company's revenues by $90M-$100M per quarter, or about $380M annually. If TD Ameritrade (AMTD) and E-Trade (ETFC) were to match Schwab's announcement, Nance estimates a 21% impact to TD Ameritrade's 2020 consensus EPS forecast and a 17% impact to E-Trade's 2020 consensus EPS forecast. He has Neutral ratings on Interactive Brokers (IBKR) and TD Ameritrade and Buy ratings on Charles Schwab and E-Trade.
10/03/19
WELS
10/03/19
DOWNGRADE
WELS
Underperform
Wells Fargo downgrades E-Brokers after material commission cuts
Wells Fargo analyst Christopher Harris double downgraded TD Ameritrade (AMTD) to Underperform from Outperform and downgraded both E-Trade Financial (ETFC) and Charles Schwab (SCHW) to Market Perform from Outperform. He also reducing his rating on the Broker coverage sector to Market Weight from Overweight. Harris maintains an Underperform rating on Interactive Brokers (IBKR). While admitting he doesn't like to lower ratings a material event, namely the reduction of certain trading commission rates to zero, the analyst believes that "identifying a bull case for this group now has become very difficult." Organic growth is slowing, interest rates are declining and "significant chunks of trading revenue are going away," Harris tells investors in a research note. The only positives he sees, other than the possibility of a short-term relief rally for the stocks, are likely expense cuts and stock buybacks. However, earnings benefits from those sort of actions don't deserve a very high multiple, contends Harris. His double downgrade of TD Ameritrade reflects the company's "current worst-in-class" earnings growth profile, corporate governance "missteps," and fewer idiosyncratic drivers of upside relative to peers.
RYTM Rhythm Pharmaceuticals
$20.90

0.52 (2.55%)

07/12/19
STFL
07/12/19
UPGRADE
Target $34
STFL
Buy
Rhythm Pharmaceuticals upgraded to Buy from Hold at Stifel
Stifel analyst Derek Archila upgraded Rhythm Pharmaceuticals to Buy from Hold with an unchanged price target of $34. The analyst sees an attractive entry point into the shares given setmelanotide's positive Phase 2 data, which he says demonstrated a meaningful benefit on weight loss and hunger scores. Both Phase 3 studies, expected in Q3, will likely be positive and a "homerun" scenario could move the stock to the low $40 range, Archila tells investors in a research note.
03/13/19
LTCO
03/13/19
INITIATION
Target $43
LTCO
Buy
Rhythm Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Michael Higgins started Rhythm Pharmaceuticals with a Buy rating and $43 price target.
03/13/19
LTCO
03/13/19
INITIATION
Target $43
LTCO
Buy
Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target
Ladenburg Thalmann analyst Michael Higgins initiated coverage of Rhythm Pharmaceuticals with a Buy rating and $43 price target. Rhythm is developing setmelanotide, a novel weight-loss drug for ultra-orphan genetic obesity disorders caused by mutations in the melanocortin-4 receptor signaling pathway, Higgins tells investors in a research note. The analyst urges investors to accumulate a position ahead of upcoming 2019 milestones, particularly pro-opiomelanocortin and leptin receptor deficiency pivotal data in Q3. Target $43.
03/13/19
03/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Outperform at Bernstein. 2. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at Ladenburg. 3. Solaris Oilfield (SOI) initiated with a Buy at B. Riley FBR. 4. Americold Realty Trust (COLD) initiated with a Buy at Berenberg. 5. Cheniere Energy (LNG) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PRQR ProQR Therapeutics
$6.21

-0.09 (-1.43%)

02/20/19
SBSH
02/20/19
NO CHANGE
SBSH
Buy
Citi opens 90-day catalyst watch on ProQR Therapeutics
Citi analyst Yigal Nochomovitz opened a 90-day catalyst watch on ProQR Therapeutics in anticipation of the interim Phase 1/2 Wings data for QR-313 in dystrophic epidermolysis bullosa. On positive data, or evidence of exon skipping in biopsies and evidence of skin lesion/blister resolution, the analyst sees the stock up 15%-25%. On negative data, he sees downside of 10%-15%. Nochomovitz has a Buy rating on ProQR Therapeutics.
03/27/19
CANT
03/27/19
NO CHANGE
Target $40
CANT
Overweight
ProQR Therapeutics spin-out 'smart, but not surprising,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle thinks ProQR Therapeutics' spin-out of its dystrophic epidermolysis bullosa program is a "smart, but not surprising," strategic move. Given that the company has communicated it wants to focus on its ophthalmology programs, investors are unlikely to find this announcement about the skin program spin-out surprising, Merle tells investors in a research note. The analyst keeps an Overweight rating on ProQR Therapeutics with a $40 price target.
10/09/19
CANT
10/09/19
NO CHANGE
Target $40
CANT
Overweight
ProQR shares could more than double on tomorrow's data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle reiterates an Overweight rating on ProQR Therapeutics with a $40 price target ahead of tomorrow's data update on lead program QR-110, which is in development for LCA10, a rare genetic form of blindness. Investors view ProQR and QR-110 as a "show-me story," but these data could lift a "significant overhang" around platform safety and serve as a "key piece of clinical de-risking" for QR-110's Phase 2/3 trial under way, Merle tells investors in a research note partially titled "A double by this time tomorrow?". The analyst thinks the stock could trade up 50%-150% tomorrow versus downside to its cash position of ~$2 per share, or ~65%.
10/10/19
SBSH
10/10/19
NO CHANGE
Target $40
SBSH
Buy
ProQR Therapeutics price target raised to $40 from $34 at Citi
Citi analyst Yigal Nochomovitz raised his price target on ProQR Therapeutics to $40 from $34, stating that he disagree's with the market's initial take on the company's updated data on sepofarsen. Given his view that the 12-month data validate the treatment benefits observed at 3 months, Nochomovitz increased his odds on the success for sepofarsen in patients with Leber's congenital amaurosis 10 to 70% from 50% and keeps his Buy rating on the stock. In afternoon trading, ProQR shares are down 26c, or 4%, to $5.95.
NTRA Natera
$39.21

1.01 (2.64%)

10/11/19
PIPR
10/11/19
NO CHANGE
Target $45
PIPR
Overweight
Natera oncology opportunity 'remains strong,' says Piper Jaffray
Piper Jaffray analyst William Quirk keeps an Overweight rating on Natera with a $45 price target after the company hosted a conference call to discuss its oncology offering. Management has a clear plan to access the oncology market via partnerships with Foundation Medicine and BGI, and their own direct channels, Quirk tells investors in a research note partially titled "Oncology Opportunity Remains Strong". The analyst estimates the initial Signatera market opportunity for colorectal cancer is ~$4.4B. While smaller than his initial expectations, Quirk continues to believe the long-term opportunity "remains robust" as Natera expands the assay to other cancers and gains traction with clinical and pharma customers.
09/12/19
ADAM
09/12/19
NO CHANGE
Target $38
ADAM
Buy
Natera reiterated a Top Pick at Canaccord
Canaccord analyst Mark Massaro met with Natera management and came away confident in his view the shares remain an undervalued cancer company trading at the multiple of an NIPT company. The analyst said its near-term pipeline is loaded and the company is expected to announce oncology deals in the near future. Massaro reiterated his Buy rating and $38 price target on Natera shares.
09/24/19
PIPR
09/24/19
NO CHANGE
Target $45
PIPR
Overweight
Natera price target raised to $45 from $32 at Piper Jaffray
Piper Jaffray analyst William Quirk said Natera's partnership with Foundation Medicine for the Signatera assay complements Natera's own direct channels and broadens the utility of the assay to late stage cancers. The analyst, who also thinks the deal increases Natera's access to large customer groups, increased his price target on Natera shares to $45 from $32 and keeps an Overweight rating on the stock.
08/22/19
PIPR
08/22/19
NO CHANGE
PIPR
Overweight
Piper says Natera gets draft LCD for Signatera CRC assay ahead of schedule
Piper Jaffray analyst William Quirk reported that Palmetto issued a draft Local Coverage Determination, or LCD, for Natera's Signatera colorectal assay, noting this was ahead of schedule as management had guided for the end of 2019 or early 2020. The draft LCD is "generally favorable," as the company will get a series of payments for minimal disease monitoring and a final LCD would open a greater than $8B opportunity for Natera, according to Quirk, who keeps an Overweight rating on Natera shares.
PRNB Principia Biopharma
$29.88

0.7 (2.40%)

07/01/19
HCWC
07/01/19
INITIATION
Target $55
HCWC
Buy
Principia Biopharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Principia Biopharma with a Buy rating and $55 price target. The company's PRN1008 could deliver a new therapy in pemphigus vulgaris and also offers a "meaningful" commercial opportunity in immune thrombocytopenia, Pantginis tells investors in a research note.
10/02/19
STFL
10/02/19
NO CHANGE
Target $45
STFL
Buy
Stifel remains buyer of Principia Biopharma into Q4 data readouts
Stifel analyst Derek Archila remains bullish and a buyer of Principia Biopharma (PRNB) shares ahead of the company's two Phase 2 readouts for PRN1008 in immune thrombocytopenia and pemphigus vulgaris. The shares could reach the mid-$50 range if results are positive, Archila tells investors in a research note. He believes the bogey for each study is not that high and keeps a Buy rating on Principia with a $45 price target. The two clinical catalysts, coupled with Phase 2 data expected in the first half of 2020 from the company's partnered program with Sanofi (SNY) in multiple sclerosis, offers "multiple shots for valuation creation" over the next nine months.
10/10/19
HCWC
10/10/19
NO CHANGE
HCWC
Principia announces 'positive' data from Phase 2 trial, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $55 price target on Principia Biopharma after the company announced positive interim data from the open label Part B of its PRN1008 Phase 2 trial in pemphigus vulgaris, or PV, which included the selection of an optimized dosing. In a note to investors titled 'Consistency Is the Message of the Day for PV Efficacy,' the analyst said the Phase 2 results helped to boost his confidence in the ongoing Pegasus Phase 3 trial of PRN1008 in PV.
10/10/19
STFL
10/10/19
NO CHANGE
Target $51
STFL
Buy
Principia Biopharma price target raised to $51 from $45 at Stifel
Stifel analyst Derek Archila raised his price target on Principia Biopharma shares to $51 from $45 after the company reported PRN1008 has demonstrated a complete response rate ahead of his expectations thus far in the company's its Phase 2 extension study in pemphigus vulgaris. More importantly, PRN1008 replicated its benign safety and tolerability profile at 24 weeks, even at higher dosing, Archila tells investors. The analyst, who said he would be "buying the stock here," maintains a Buy rating and keeps it on Stifel's Select List.
X U.S. Steel
$11.43

0.27 (2.42%)

10/02/19
BMOC
10/02/19
NO CHANGE
Target $12
BMOC
Market Perform
U.S. Steel's Big River Steel deal is 'meaningful transaction', says BMO Capital
BMO Capital analyst David Gagliano says the $700M acquisition of Big River Steel by U.S. Steel is a "meaningful transaction" in that it provides the latter with a "low operating-cost, growth asset" which positions it better over the long term. The analyst is keeping his Market Perform rating and $12 on the stock however, noting that the debt-financed deal adds even more debt to U.S. Steel, which is is also paying a "fairly high" implied valuation.
09/23/19
JPMS
09/23/19
DOWNGRADE
Target $14
JPMS
Neutral
U.S. Steel downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Gambardella downgraded U.S. Steel to Neutral from Overweight and lowered his price target for the shares to $14 from $26.
09/23/19
JPMS
09/23/19
DOWNGRADE
JPMS
Underweight
JPMorgan double downgrades AK Steel, cuts U.S. Steel on flattish price outlook
JPMorgan analyst Michael Gambardella earlier today lowered his estimates and price targets for the steel companies to reflect a "more flattish" steel price environment. The analyst also double downgraded AK Steel (AKS) to Underweight from Overweight and downgraded U.S. Steel (X) to Neutral Overweight. He removed U.S. Steel from his firm's Analyst Focus List. The U.S. steel stocks and steel prices have been under pressure this year, which is largely due to concerns about supply additions planned for the next several years, continued uncertainty surrounding trade, and some softening in demand, Gambardella tells investors in a research note. Further, after a brief rebound, steel and scrap prices are now heading lower, adds the analyst. He kept Overweight ratings on Commercial Metals (CMC), Nucor (NUE), Steel Dynamics (STLD), and Stelco Holdings (STZHF).
09/23/19
09/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alcoa (AA) downgraded to Neutral from Buy at Goldman Sachs. 2. Commercial Metals (CMC) was downgraded to Neutral from Buy at Goldman Sachs while Schnitzer Steel (SCHN) was downgraded to Sell from Neutral. 3. AK Steel (AKS) was downgraded to Underweight from Overweight at JPMorgan while Cleveland-Cliffs (CLF) and U.S. Steel (X) were downgraded to Neutral from Overweight. 4. Clorox (CLX) downgraded to Underweight from Equal Weight at Barclays. 5. Spirit Airlines (SAVE) downgraded to Equal Weight from Overweight at Stephens with analyst Jack Atkins saying with its heavy Southeast and Caribbean exposure, Spirit significantly lowered its Q3 guidance in early September due to Hurricane Dorian. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ARCE Arco Platform
$48.15

0.75 (1.58%)

11/21/18
UBSW
11/21/18
INITIATION
Target $28
UBSW
Buy
Arco Platform initiated with a Buy at UBS
UBS analyst Maria Tereza Azevedo started Arco Platform with a Buy rating and $28 price target. The analyst views Arco as an "attractive investment proposition" given its "unique" product and market position in the private Brazilian K-12 learning system sector. She likes the company's software-as-a-service type and asset/regulatory-light business model.
06/25/19
FBCO
06/25/19
INITIATION
Target $46
FBCO
Neutral
Arco Platform initiated with a Neutral at Credit Suisse
Credit Suisse initiated Arco Platform with a Neutral and $46 price target.
08/29/19
BOFA
08/29/19
INITIATION
Target $58
BOFA
Buy
Arco Platform reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Pedro Mariani reinstated coverage of Arco Platform with a Buy rating and $58 price target, which implies 17% upside potential. Arco has developed a successful business model by creating a "win-win-win relationship" with schools, Mariani tells investors in a research note. He believes the company has strong brand equity in the Brazilian private K-12 education market. The analyst sees Arco leading the transformation of the K-12 segment, which he thinks should drive further market share expansion.
11/21/18
11/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BeiGene (BGNE) initiated with an Overweight at JPMorgan. 2. Gamida Cell (GMDA) initiated with an Outperform at BMO Capital and Oppenheimer. 3. Marker Therapeutics (MRKR) initiated with a Buy at Nomura Instinet. 4. Arco Platform (ARCE) initiated with a Buy at UBS. 5. nVent Electric (NVT) initiated with a Hold at Vertical Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TW Tradeweb Markets
$39.79

-0.14 (-0.35%)

10/01/19
LEHM
10/01/19
UPGRADE
Target $45
LEHM
Overweight
Tradeweb Markets upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jeremy Campbell upgraded Tradeweb Markets to Overweight from Equal Weight with a price target of $45.
10/01/19
LEHM
10/01/19
UPGRADE
Target $45
LEHM
Overweight
Barclays upgrades Tradeweb Markets to Overweight after pullback
Barclays analyst Jeremy Campbell upgraded Tradeweb Markets to Overweight from Equal Weight with an unchanged price target of $45. Recent weakness in the shares "seems largely technical," which presents an "attractive upside opportunity," Campbell tells investors in a research note. The analyst sees $34 per share as near-term valuation support with upside back to the low-to-mid $40's. Further, with exchange sentiment high and structural growth stories in demand, the market to absorb any forthcoming supply from the lock-up expiration, and Tradeweb has balance sheet flexibility to "buy-back some unlocked stock," says Campbell.
10/01/19
10/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ericsson (ERIC) upgraded to Buy from Hold at Canaccord with analyst Michael Walkley saying since the Q2 earnings report, Ericsson has announced deals with Nex-Tech, RINA, and KDDI, demonstrating continuing 5G momentum. 2. VMware (VMW) upgraded to Outperform from Market Perform at Wells Fargo with analyst Philip Winslow saying investors have been concerned that growing interest in deploying containerized applications into Kubernetes-centric environments will eventually reduce customer demand for VMware's virtualization-centric product portfolio. 3. Tradeweb Markets (TW) upgraded to Overweight from Equal Weight at Barclays with analyst Jeremy Campbell saying recent weakness in the shares "seems largely technical," which presents an "attractive upside opportunity." 4. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underperform at BofA/Merrill with analyst Christopher Carey saying the bar on the company's earnings consensus may be "too low." 5. Philip Morris (PM) upgraded to Buy from Neutral at BofA/Merrill with analyst Lisa Lewandowski citing the suspended merger discussions with Altria (MO) amid the heightened risk for U.S. vaping category following reports of lung health concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/19
BOFA
09/13/19
UPGRADE
BOFA
Buy
Tradeweb Markets upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded Tradeweb Markets to Buy from Neutral with the stock down 16% since the end of July. Meanwhile, the company's volumes continue to outperform expectations and management as shown the ability to drive revenues and margin gains relative to peers, Carrier tells investors in a research note.

TODAY'S FREE FLY STORIES

20:20
11/21/19
11/21
20:20
11/21/19
20:20
General news
Treasury Market Summary »

Treasury Market Summary:…

LYV

Live Nation

$66.17

-1.55 (-2.29%)

20:08
11/21/19
11/21
20:08
11/21/19
20:08
Periodicals
Live Nation 'looking forward' to taking part in Congress review of ticket market 

Report from Bloomberg.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRH

DiamondRock

$9.86

-0.085 (-0.86%)

19:53
11/21/19
11/21
19:53
11/21/19
19:53
Upgrade
DiamondRock rating change at Wells Fargo »

DiamondRock upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OOMA

Ooma

$11.18

-0.01 (-0.09%)

, IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

19:18
11/21/19
11/21
19:18
11/21/19
19:18
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ooma…

OOMA

Ooma

$11.18

-0.01 (-0.09%)

IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

JWN

Nordstrom

$34.29

0.35 (1.03%)

SCVL

Shoe Carnival

$37.18

1.36 (3.80%)

SPLK

Splunk

$126.80

-0.04 (-0.03%)

GPS

Gap

$16.22

-0.05 (-0.31%)

ROST

Ross Stores

$111.81

1.39 (1.26%)

PSTG

Pure Storage

$19.84

-0.22 (-1.10%)

WSM

Williams-Sonoma

$68.76

0.195 (0.28%)

PNNT

PennantPark

$5.95

0.01 (0.17%)

ENTA

Enanta

$63.27

1.55 (2.51%)

INTU

Intuit

$270.01

-3.38 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 22

    Nov

  • 22

    Nov

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 10

    Mar

  • 11

    Mar

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:08
11/21/19
11/21
19:08
11/21/19
19:08
Earnings
AES backs FY19 adjusted EPS view $1.30-$1.38, consensus $1.33 »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

WM

Waste Management

$111.23

-1.305 (-1.16%)

, RSG

Republic Services

$86.78

-0.91 (-1.04%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Initiation
Waste Management, Republic Services, Waste Connections, Clean Harbors, Stericycle, Casella Waste, Covanta initiated  »

Jefferies initiates…

WM

Waste Management

$111.23

-1.305 (-1.16%)

RSG

Republic Services

$86.78

-0.91 (-1.04%)

WCN

Waste Connections

$89.54

-0.28 (-0.31%)

CLH

Clean Harbors

$84.70

-0.75 (-0.88%)

SRCL

Stericycle

$62.49

0.76 (1.23%)

CWST

Casella Waste

$43.70

-0.39 (-0.88%)

CVA

Covanta

$14.43

-0.14 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Hot Stocks
AES Corp. says PUCO has modified DP&L rates »

The AES Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

, BTC

Bitcoin

$0.00

(0.00%)

19:02
11/21/19
11/21
19:02
11/21/19
19:02
Hot Stocks
ICE announces launch of Bakkt Bitcoin Cash Settled Monthly Futures contract »

Intercontinental Exchange…

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAN

ManpowerGroup

$92.05

-0.355 (-0.38%)

18:51
11/21/19
11/21
18:51
11/21/19
18:51
Initiation
ManpowerGroup initiated at Jefferies »

ManpowerGroup initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHI

Robert Half

$58.01

-0.38 (-0.65%)

18:48
11/21/19
11/21
18:48
11/21/19
18:48
Initiation
Robert Half initiated at Jefferies »

Robert Half initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTZ

Hertz

$15.37

0.265 (1.76%)

18:46
11/21/19
11/21
18:46
11/21/19
18:46
Initiation
Hertz initiated at Jefferies »

Hertz initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$28.71

0.16 (0.56%)

18:44
11/21/19
11/21
18:44
11/21/19
18:44
Initiation
Avis Budget initiated at Jefferies »

Avis Budget initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$39.52

-1.45 (-3.54%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Hot Stocks
AMD CEO: The key for us is product generation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CTAS

Cintas

$253.61

-5.78 (-2.23%)

, BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Initiation
Cintas, Bright Horizons, Aramark, H&R Block, BrightView, Rollins, ServiceMaster initiated at Jefferies »

Jefferies initiates…

CTAS

Cintas

$253.61

-5.78 (-2.23%)

BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

ARMK

Aramark

$42.42

-1.37 (-3.13%)

HRB

H&R Block

$24.34

-0.15 (-0.61%)

BV

BrightView

$16.79

-2.525 (-13.08%)

ROL

Rollins

$35.77

-0.8 (-2.19%)

SERV

ServiceMaster

$36.16

-0.42 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

PINE

Alpine Income Properties

$0.00

(0.00%)

18:34
11/21/19
11/21
18:34
11/21/19
18:34
Syndicate
Alpine Income Properties 7.5M share IPO priced at $19.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

OTTW

Ottawa Bancorp

$13.39

-0.39 (-2.83%)

18:28
11/21/19
11/21
18:28
11/21/19
18:28
Hot Stocks
Ottawa Bancorp approves stock buyback of 317,307 shares »

Ottawa Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$149.46

-0.14 (-0.09%)

18:27
11/21/19
11/21
18:27
11/21/19
18:27
Periodicals
Microsoft says granted U.S. license to do business with Huawei, Bloomberg says »

Microsoft said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

SITC

Site Centers

$14.28

-0.275 (-1.89%)

18:24
11/21/19
11/21
18:24
11/21/19
18:24
Upgrade
Site Centers rating change at Stifel »

Site Centers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Airlines

$90.96

-0.72 (-0.79%)

, BA

Boeing

$366.47

-4.275 (-1.15%)

18:23
11/21/19
11/21
18:23
11/21/19
18:23
Hot Stocks
United Airlines CEO: We don't think we are near a recession »

In an interview on…

UAL

United Airlines

$90.96

-0.72 (-0.79%)

BA

Boeing

$366.47

-4.275 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FAST

Fastenal

$35.15

-0.1 (-0.28%)

, GWW

Grainger

$312.66

0.305 (0.10%)

18:20
11/21/19
11/21
18:20
11/21/19
18:20
Initiation
Fastenal, Grainger, HD Supply, MSC Industrial, Wesco initiated at Jefferies »

Jefferies initiates…

FAST

Fastenal

$35.15

-0.1 (-0.28%)

GWW

Grainger

$312.66

0.305 (0.10%)

HDS

HD Supply

$39.10

-0.21 (-0.53%)

MSM

MSC Industrial

$73.66

-0.125 (-0.17%)

WCC

Wesco

$53.09

-0.02 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 30

    Jan

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

, INFO

IHS Markit

$71.62

-0.38 (-0.53%)

18:06
11/21/19
11/21
18:06
11/21/19
18:06
Initiation
S&P Global, IHS Markit, Verisk Analytics, Gartner, FactSet, Equifax, TransUnion, CoStar Group initiated at Jefferies »

Jefferies initiates…

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

INFO

IHS Markit

$71.62

-0.38 (-0.53%)

VRSK

Verisk Analytics

$144.45

0.12 (0.08%)

IT

Gartner

$158.00

0.06 (0.04%)

FDS

FactSet

$258.20

-3.65 (-1.39%)

EFX

Equifax

$137.97

-1.15 (-0.83%)

TRU

TransUnion

$84.90

-1.34 (-1.55%)

CSGP

CoStar Group

$587.66

-7.45 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 19

    Dec

  • 19

    Dec

  • 07

    Jan

GPS

Gap

$16.22

-0.05 (-0.31%)

17:59
11/21/19
11/21
17:59
11/21/19
17:59
Periodicals
Gap to pull Old Navy brand from China in early 2020, Reuters reports »

Gap said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

LB

L Brands

$17.18

1.78 (11.56%)

17:50
11/21/19
11/21
17:50
11/21/19
17:50
Hot Stocks
L Brands cancels Victoria's Secret Fashion Show for 'more current platforms' »

The CFO of L Brands,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

  • 27

    Feb

WCC

Wesco

$53.09

-0.02 (-0.04%)

17:47
11/21/19
11/21
17:47
11/21/19
17:47
Initiation
Wesco initiated at Jefferies »

Wesco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAN

ManpowerGroup

$92.05

-0.355 (-0.38%)

17:47
11/21/19
11/21
17:47
11/21/19
17:47
Initiation
ManpowerGroup initiated at Jefferies »

ManpowerGroup initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.